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Recent genome-wide association studies have identified over 230 genetic risk loci for
multiple sclerosis. Current experimental autoimmune encephalomyelitis (EAE) models
requiring active induction of disease may not be optimally suited for the characterization
of the function of these genes. We have thus used gene expression profiling to study
whether spontaneous opticospinal EAE (OSE) or MOG-induced EAE mirrors the genetic
contribution to the pathogenesis of multiple sclerosis more faithfully. To this end, we
compared gene expression in OSE and MOG EAE models and analyzed the relationship
of both models to human multiple sclerosis risk genes and T helper cell biology. We
observed stronger gene expression changes and an involvement of more pathways of
the adaptive immune system in OSE than MOG EAE. Furthermore, we demonstrated
a more extensive enrichment of human MS risk genes among transcripts differentially
expressed in OSE than was the case for MOG EAE. Transcripts differentially expressed
only in diseased OSE mice but not in MOG EAE were significantly enriched for T helper
cell-specific transcripts. These transcripts are part of immune-regulatory pathways. The
activation of the adaptive immune system and the enrichment of both human multiple
sclerosis risk genes and T helper cell-specific transcripts were also observed in OSEmice
showing only mild disease signs. These expression changes may, therefore, be indicative
of processes at disease onset. In summary, more human multiple sclerosis risk genes
were differentially expressed in OSE than was observed for MOG EAE, especially in TH1
cells. When studying the functional role of multiple sclerosis risk genes and pathways
during disease onset and their interactions with the environment, spontaneous OSE may
thus show advantages over MOG-induced EAE.
Keywords: experimental autoimmune encephalomyelitis (EAE), myelin oligodendrocyte glycoprotein (MOG), T
helper cell (Th), multiple sclerosis, risk genes, gene expression
INTRODUCTION
Although animal models are widely used in human research, it is still discussed whether they
can adequately mirror diseases like multiple sclerosis (MS) that only exist in humans. MS is a
chronic inflammatory disease of the central nervous system (CNS), with both environmental and
genetic risk factors contributing to disease susceptibility. The recent identification of more than 230
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genetic risk loci for MS (1, 2) requires a reassessment of
the widely used experimental autoimmune encephalomyelitis
(EAE) animal models. To support analyses of the primary cause
and etiology of MS, animal models should ideally replicate
mechanisms taking place during MS disease induction.
Most EAE models are actively induced by injection of myelin-
derived antigens in conjunction with potent adjuvants (3). One
such antigen is myelin oligodendrocyte glycoprotein (MOG), a
component of the outer surface of myelin (4). Injection of the
MOG35−55 peptide into C57BL/6 mice leads to chronic EAE (5)
and thus serves as a popular animal model to date. A related
model, passively-transferred EAE, is caused by bulk transfer of
in vitro-activated myelin-specific T cells (6).
By contrast, transgenic models such as opticospinal EAE
(OSE) spontaneously develop autoimmune disease and may,
therefore, be better suited to study disease onset than induced
EAE is. Spontaneous models can be used for identifying
environmental triggers of MS (7, 8) and might support analyses
of genetic risk factors for human MS. They circumvent problems
specific to induced ones, such as adjuvant inoculation, with
its partially unknown effects. In OSE, ∼50% of the animals
develop a spontaneous inflammatory demyelinating CNS disease,
predominantly affecting optic nerves and the lumbar part of the
spinal cord (9). These mice carry two transgenic modifications:
they express a T cell receptor (TCR) recognizing the MOG35−55
peptide and B cells with MOG-specific receptors. In OSE, MOG-
specific B cells function as antigen-presenting cells to trigger
disease onset by activating MOG-specific T cells (10). Notably,
B cell-depleting treatments for MS appear to target primarily
cellular and not humoral B cell responses, and, thus, result in a
reduced T cell activation (11).
For a long time, TH1 cells were considered as the predominant
drivers of EAE and MS (4). This hypothesis was challenged by
emerging evidence for a substantial role of TH17 cells in the
disease etiology, including the discovery that the transfer of TH17
cells can induce EAE. In fact, both TH cell types can induce EAE,
albeit with distinct pathologies (12). In humans, genome-wide
association studies (GWAS) have identified many MS risk loci
that support a central role of TH cells and TH cell differentiation
in the pathophysiology of MS (1, 2, 13).
Despite their valuable contributions to our understanding
of MS pathophysiology and drug development, the relationship
of EAE to human MS remains controversial (14). All available
EAE models are, to some degree, artificial. Therefore, knowledge
of whether gene expression changes in diseased mice involve
MS risk genes can support the choice of an EAE model
for specific research projects. The present study had three
aims: First, to characterize gene expression differences in
diseased OSE and MOG35−55 EAE mice, two widely used
EAE models with markedly different forms of induction.
Second, to explore which of OSE or MOG-induced EAE
resembles human MS more closely. To this end, we examined
to which degree genes differentially expressed in spinal
cord samples of OSE and MOG EAE showed significant
enrichment of human MS risk genes. Third, to analyze
expression differences of TH cell-specific transcripts in both
EAE models.
MATERIALS AND METHODS
Mice, Animal Handling, and Scoring
All mice used in this study had a C57BL/6 background and
were bred in the animal facilities of the Max Planck Institute of
Biochemistry and Neurobiology, Martinsried, Germany. For the
OSE model, double-transgenic 2D2 (TCRMOG)× IgHMOG (OSE)
mice were used (9). For MOG EAE, wildtype C57BL/6 mice
were immunized subcutaneously with 200 µg of a MOG peptide
consisting of the amino acids 35–55, emulsified in complete
Freund’s adjuvant supplemented with 5 mg/ml Mycobacterium
tuberculosis (strain H37Ra, Thermo Fischer Scientific BD Difco),
as described previously (9). Pertussis toxin (400 ng, List
Biological Laboratories) was injected intraperitoneally on the day
of immunization and 48 h later. Control mice (CFA) received the
same treatment but without the MOG peptide. For the analysis
of EAE models, only female mice were used. For the TH cell
analyses, OSE mice of mixed gender were used (15).
Scores for clinical signs of EAE were assessed daily according
to the standard 5-point scale (9, 16): 0: healthy animal; 1:
animal with a flaccid tail; 2: animal with impaired righting
reflex and/or gait; 3: animal with one paralyzed hind leg; 4:
animal with both hind legs paralyzed; 5: moribund animal
or death of the animal after preceding clinical disease. See
Supplementary Figure 1 for the disease course of MOG EAE
compared to control mice. Following our ethically approved
protocol, the mice were sacrificed when they reached a
score of 4. The animal welfare committee of the government
of Upper Bavaria (Tierschutzkommission der Regierung von
Oberbayern, Munich, Germany) approved the protocol. The
animal procedures were in strict accordance with the guidelines
set down by the animal welfare committee of the government of
Upper Bavaria.
In vitro CD4+ T Cell Differentiation
T cells derived from the spleen of a mixed-gender pool of four
OSE mice were used to polarize pathogenic effector TH1 and
TH17 cells, as described previously (15). In brief, four separate
batches of four mice each were used for this experiment. To
generate TH1 cells, total erythrocyte-lysed spleen cells from OSE
mice were cultured in the presence of a MOG peptide (amino
acids 1–125), IL-12, IL-18, and anti-IL-4. After 3 days, IL-2 was
added to the culture. To generate TH17 cells, total erythrocyte-
lysed spleen cells from OSE mice were cultured in the presence
of a MOG peptide (amino acids 1–125), TGF-β1, IL-6, IL-23,
anti-IL-4, and anti-IFN-γ. After 3 days, IL-23 was added to
the culture. In both cases, cells were re-stimulated after 6 days
and harvested after 9 and, once more, after 12 days. Naïve TH0
cells were harvested on day 0. The success of polarization was
evaluated by flow cytometry, ELISA, and quantitative real-time
PCR (Supplementary Figure 2 and Supplementary Methods).
Microarrays
Two separate microarray experiments were performed on the
Illumina gene expression profiling platform: The first comprised
RNA isolated from total spinal cord preparations of healthy
and diseased EAE mice. The second experiment analyzed gene
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expression profiles of naïve TH0 cells and in vitro polarized TH1
and TH17 cells. For the analysis of EAE models, the Sentrix
BeadChip ArrayMouseWG-6 v2 (Illumina, San Diego, USA) was
used; for the TH cell microarray, the Sentrix BeadChip Array
MouseWG-6 v1.1 (Illumina, San Diego, USA). Four chips (24
samples, four per experimental group) were hybridized in the
EAE experiment, three chips (18 samples from four separate
experiments: 4 × TH0, 7 × TH1, 7 × TH17) were used for the
TH cell analysis. In each experiment, all samples and chips were
processed in parallel. RNA processing, array hybridization, and
quantification followed the same protocols in both experiments:
First, concentration and purity of total RNA were assessed
by 260 nm UV absorption and by 260/280 ratios, respectively
(Nanophotometer, Implen, Munich, Germany). Second, RNA
integrity was evaluated using a chip-based electrophoretic assay
(Agilent RNA 6000 Nano Kit used in conjunction with the
Agilent 2100 bioanalyzer, Agilent Technologies, Waldbronn,
Germany). Mean RNA integrity numbers were 8.4 (SD = 0.5)
for the EAE and 9.0 (SD = 0.5) for the TH cell experiment.
Third, RNA was amplified and labeled using the Illumina
TotalPrep RNA Amplification Kit (Ambion, Houston, TX, USA)
and hybridized onto Illumina gene expression arrays following
the manufacturer’s instructions. Fourth, fluorescence signals
were scanned on an Illumina BeadStation and analyzed by in-
house software routines. The manufacturer’s built-in controls
were analyzed, including hybridization controls and sample-
dependent parameters. All microarrays fulfilled Illumina’s
recommendations for quality control (QC).
Quality Control of Microarrays
Raw probe intensities were exported as summary data using
Illumina’s GenomeStudio, and further statistical processing was
carried out using R v3.3.2 (17). For the analysis of EAE
models, summary data was loaded using the Bioconductor
package beadarray (18), and QC was conducted with lumi (19)
and vsn (20). Each probe was transformed and normalized
through variance stabilization and normalization. Probes were
removed if they showed a detection p-value < 0.05 in
>10% of the samples or had a “no match” or “bad” probe
quality in the illuminaMousev2.db package. This procedure
left 21,483 transcripts from 24 samples. For the TH cell
experiment, summary data was loaded using limma (21)
and QC was conducted with limma and vsn. Probes were
transformed, normalized, and filtered as described above, based
on the illuminaMousev1p1.db package. This pipeline left 17,858
transcripts. Technical batch effects were examined by inspecting
the association of the first ten principal components of expression
levels with expression chip and position on the chip.
Analysis of Differential Expression
Principal component analysis (PCA) was conducted in R using
the function prcomp without scaling of variables; PCs were
scaled for display. K-means clustering was performed using
kmeans with k = 4; the analysis was repeated 100 times and
the most stable clustering solution was selected. Differential
expression was assessed with limma. For the analysis of
differential expression across the EAE models, six mouse types
were examined (with four mice each): wild-type (WT); healthy
OSE controls (OSE0); OSE with disease score 1 (OSE1); OSE
score 4 (OSE4); as a MOG EAE control, healthy control mice
injected with complete Freund’s adjuvant but not with a MOG
peptide (CFA); as MOG35−55 EAE, C57BL/6 wildtype mice
injected with adjuvant and MOG35−55 peptide, rated score 4
(MOG4). The design matrix was constructed from the six mouse
types. Each expression chip contained one sample per mouse
type. The four chips were added to the model as random effects
via the duplicateCorrelation function. The five contrasts MOG4-
CFA, CFA-WT, OSE4-OSE0, OSE1-OSE0, and OSE4-WT were
computed on the fitted linear model and moderated t-tests were
calculated using the eBayes function. For the TH cell experiment,
the design matrix was constructed from the three cell types
(naïve TH0, TH1, TH17), with the four mouse pools treated
as random effects. Only TH1 and TH17 cells harvested on day
9 were analyzed. The two contrasts TH1-TH0 and TH17-TH0
were examined.
Overrepresentation Analyses
Overrepresentation analyses (ORA) were conducted using
WebGestalt v2019 (22) in R, based on the gene ontology
(GO) biological process database. Genes were submitted as
unique Entrez IDs, and the reference was genome protein-coding.
The significance level was determined using a hypergeometric
test, followed by calculation of the Benjamini-Hochberg false
discovery rate (FDR) (23).
Enrichment Tests
The enrichment of genes was calculated using a permutation test
in R. For this test, the unique Entrez IDs of genes were used.
First, the amount of unique differentially expressed genes was
determined, and the same number of random genes was selected.
Second, the number of these random genes overlapping with the
test set of genes (e.g., MS susceptibility genes) was determined.
These two steps were repeated 100,000 times. Third, to calculate
a p-value, the number of observations where the overlap between
random genes and test genes was equal to or larger than the
overlap between differentially expressed genes and test genes was
counted and divided by the number of permutations.
For the enrichment analysis with MS susceptibility genes, the
558 genes outside the major histocompatibility complex (MHC)
region listed in Supplementary Table 18 of the MS genomic map
published in 2019 by the IMSGC were used (2). From this list,
CTB-50L17.10, RP11-345J4.5, JAZF1-AS1, ZEB1-AS1, GATA3-
AS1, SSTR5-AS1, and RPL34-AS1 were excluded to generate the
list of 551 prioritized putative MS susceptibility genes described
in the IMSGC publication.
RESULTS
We compared gene expression profiles of total spinal cord
preparations derived from two EAE models, OSE and
MOG35−55 EAE. Double-transgenic OSE mice developed
CNS autoimmunity spontaneously, predominantly affecting
the lumbar part of the spinal cord. In the MOG35−55 EAE
model, the disease was induced in C57BL/6 wildtype (WT)
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FIGURE 1 | Differential expression analysis of OSE and MOG EAE models. (A) Principal component analysis (PCA) of gene expression profiles grouped by k-means
clustering. The cluster solution displayed here was the most frequent (34 of 100). In 97 of 100 analyses, all WT, OSE0, and CFA mice were placed into separate
clusters than OSE1, OSE4, and MOG4 mice (Supplementary Table 1). Because of the spontaneous nature of disease development in OSE mice, gene expression in
diseased OSE4 animals showed more variance than was, e.g., observed in MOG4 mice, which exhibit a more stereotypic disease course (9). PC, principal
component; SD, standard deviations. (B) Venn diagram highlighting the number of transcripts differentially expressed in the analyzed contrasts. For this plot, up- and
downregulated transcripts were analyzed separately, and transcripts differentially expressed in opposing directions are therefore included in the counts. (C,D) OSE4
mice showed greater fold changes of expression levels than (C) OSE1 and (D) MOG4 mice, each compared to its control condition (OSE0 and CFA, respectively)
(Supplementary Table 3). For each group, the ten most differentially expressed genes (with Entrez IDs) are labeled. If two probes per gene were present among the
top differentially expressed transcripts, the gene was counted only once, but both probes are plotted. The groups are: differentially expressed in OSE1 only (light
magenta), differentially expressed in OSE4 only (dark magenta), differentially expressed in MOG4 only (red), differentially expressed in (C) both OSE1 and OSE4 or (D)
both MOG4 and OSE4 (brown; with higher expression levels observed for OSE4 ).
mice by immunization with a MOG35−55 peptide. PCA of gene
expression profiles separated healthy (OSE0, CFA, andWT) from
diseased [OSE score 1 (OSE1), OSE score 4 (OSE4), and MOG
score 4 (MOG4)] animals along the first component (Figure 1A).
Most variance in gene expression was thus observed between
healthy and diseased mice and not between EAEmodels. Because
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of the spontaneous nature of disease development in OSE mice,
gene expression in diseased OSE4 animals showed more variance
than was, e.g., observed in MOG4 mice, which exhibit a more
stereotypic disease course (9).
Unsupervised k-means clustering on PCs further supported
this finding, which consistently (in 97 of 100 replications) placed
healthy and diseased animals into separate clusters (Figure 1A,
Supplementary Table 1). The most frequent cluster solution
(34/100) placed all healthy mice together in cluster 1; additional
clusters were OSE1 only (cluster 2), OSE4 only (cluster 3), and a
mixed cluster of the remaining diseased animals (cluster 4). We
could thus successfully detect disease-relevant gene expression
changes in the animals.
Stronger Gene Expression Changes in the
OSE Model
Next, we analyzed gene expression changes in OSE and
MOG EAE mice. We examined differential expression for
five contrasts: OSE1-OSE0, OSE4-OSE0, MOG4-CFA, and the
two control contrasts CFA-WT and OSE0-WT (Figure 1B,
Supplementary Table 2). In the control contrast CFA-WT, no
transcript was differentially regulated. A single transcript was
upregulated in OSE0-WT, T cell receptor alpha chain (Tcra),
which was also upregulated in all other contrasts except CFA-
WT. The number of significantly up- and downregulated
transcripts was higher for OSE4-OSE0 (n = 5,555) than
for MOG4-CFA (n = 3,182). In total, the expression of
864 transcripts differed significantly between MOG4 and
OSE4 mice (Supplementary Table 2). Interestingly, 4.88× more
transcripts were differentially expressed specifically only in
OSE4-OSE0 than only in MOG4-CFA (Figure 1B). Moreover,
fold changes were higher in OSE4-OSE0 than in either OSE1-
OSE0 (binomial test: p = 1.4 × 10
−65 for all transcripts,
p = 9.9 × 10−119 for transcripts differentially expressed
in both contrasts, Figure 1C) or MOG4-CFA (p = 5.8 ×
10−3 for all, p = 2.7 × 10−221 for differentially expressed
transcripts, Figure 1D; Supplementary Table 3). Stronger global
gene expression changes were thus triggered in OSE than in
MOG EAE.
Overrepresentation of Immune System
Processes Especially for OSE
To characterize the expression changes in the different EAE
models further, we conducted ORA analyses of the analyzed
contrasts (Supplementary Table 4, Supplementary Figure 3)
and of differentially expressed transcripts for three groups
(Supplementary Figure 4): First, common disease transcripts
(CDT), differentially expressed for both contrasts OSE4-
OSE0 and MOG4-CFA but not in the two control contrasts
OSE0-WT or CFA-WT. Second, OSE4-specific transcripts
(OSE4sp), differentially expressed for the contrast OSE4-
OSE0 but not for MOG4-CFA or the control contrasts.
Third, MOG4-specific transcripts (MOG4sp), differentially
expressed for MOG4-CFA but not for OSE4-OSE0 or the
control contrasts. When examining CDT, 1,379 redundant
GO biological processes remained significant after correction
for multiple testing (Supplementary Table 4). Together
with other immune-related gene sets, immune response,
regulation of immune system process, and T cell activation
were among the top-associated terms (adjusted p < 2
× 10−16). These and other immune-associated processes
remained significant in OSE4sp (adjusted p ≤ 3.5 × 10
−2,
Supplementary Figure 4). By contrast, no immune system-
specific process was significant for MOG4sp. More expression
changes in the immune system were, therefore, triggered in OSE
than in MOG EAE.
Activation of the Adaptive Immune System
in OSE1 Mice
While MOG EAE develops rapidly in a highly stereotypical
manner, the clinical course of OSE is usually slower and
shows more inter-individual variability (24). OSE thus allows
for studying disease at different stages, and we analyzed mice
showing a mild disease score of 1 (OSE1). Compared to
OSE0, 34 transcripts were differentially expressed specifically
in OSE1 animals and not in any other contrast [OSE1-specific
transcripts (OSE1sp), Supplementary Table 5]. These transcripts
are potentially indicative of changes during mild or early disease.
However, no significant GO biological processes were identified
for them. Transcripts differentially regulated in both OSE1 and
OSE4 consistently showed the same direction of regulation
compared to OSE0 [binomial test p = 4.36 × 10
−252, 95%
confidence interval (CI) 0.995–1.0, Supplementary Table 3].
When analyzing all transcripts differentially expressed in
OSE1-OSE0 but not in control contrasts [OSE1-expressed
transcripts (OSE1ex), Supplementary Table 5], 805 processes
were significant after correction for multiple gene sets. Among
them were the three previously highlighted GO terms (adjusted p
< 2× 10−16, Supplementary Table 4, Supplementary Figure 4).
Furthermore, the gene sets B cell mediated immunity and antigen
processing and presentation were significantly overrepresented
not only in the analysis of CDT but also for the OSE1ex
transcripts, indicating a potential role of B cells also in mildly
affected OSE mice.
Enrichment of MS Susceptibility Genes
Among Transcripts Expressed in OSE
Over 230 independent genetic loci associated with MS
susceptibility in humans have been identified (1, 2). Based
on these GWAS loci, 551 human MS susceptibility candidate
genes have been proposed (2), for which expression data of
499 transcripts were available in our dataset. We conducted
a PCA on these transcripts (265 genes) to analyze whether
the expression of MS risk genes was increased in the EAE
models. The first component, explaining 75.7% of the variance
in expression of these transcripts, was significantly higher in
all disease groups than in controls, indicating high expression
levels of MS-associated genes in EAE, with the highest levels
observed for OSE4 (Figure 2A, Supplementary Table 6). Also
individual MS risk genes, e.g., H2-Ab1, Cd52, and Cd86 (1, 2),
as well as further putative MS-associated genes like Cd74, were
among the transcripts showing the lowest differential expression
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FIGURE 2 | MS risk genes show a higher expression in diseased EAE animals. (A) Principal component analysis (PCA) of gene expression profiles of putative MS risk
genes. Diseased mice showed higher MS risk gene expression levels (Supplementary Table 6). PC, principal component; y-axis unit, standard deviations. (B–D)
Examples of expression levels of three putative MS risk genes, H2-Ab1, Cd52, and Cd86 (Supplementary Table 2). In all three cases, diseased mice showed
significantly higher expression levels, with the highest expression observed for OSE4 mice. Significance levels: *** adjusted p < 0.001.
TABLE 1 | Enrichment of MS susceptibility genes.
DE transcript group DE genes Overlapping genes p-value Adjusted p-value
CDT 2,014 68 <1 × 10−5 <4 × 10−5
OSE4sp 2,362 68 4.4 × 10
−4 8.8 × 10−4
MOG4sp 469 11 3.2 × 10
−1 3.2 × 10−1
OSE1ex 693 34 1.0 × 10
−5 4.0 × 10−5
Of 551 genes considered, 265 were present in our data. P-values were computed using 100,000 permutations. Enrichments significant after Holm-Bonferroni correction for multiple
testing (four tests) are highlighted in bold font (adjusted p-value < 0.05). DE, differentially expressed; WT, wildtype; CDT, common disease transcripts (differentially expressed for both
contrasts OSE4-OSE0 and MOG4-CFA but not in the two control contrasts OSE0-WT or CFA-WT); OSE4sp, OSE4-specific transcripts (differentially expressed for the contrast OSE4-
OSE0 but not in MOG4-CFA, OSE0-WT, or CFA-WT); MOG4sp, MOG4-specific transcripts (differentially expressed for the contrast MOG4-CFA but not in OSE4-OSE0, OSE0-WT, or
CFA-WT); OSE1ex, OSE1-expressed transcripts (differentially expressed in OSE1-OSE0 but not in OSE0-WT or CFA-WT).
p-values. They were significantly upregulated in all three diseased
mouse types (Figures 1C,D, 2B–D, Supplementary Figure 5,
Supplementary Table 2). Furthermore, differentially expressed
genes from the analysis sets CDT, OSE4sp, and OSE1ex
were significantly enriched for MS risk genes, while the
MOG4sp genes were not (Table 1). OSE might thus be
more closely connected to the etiology of human MS than
MOG35−55 EAE is.
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FIGURE 3 | Genes differentially expressed in TH cells show a higher expression in diseased EAE animals, especially in OSE4. (A) Venn diagram highlighting the
number of transcripts differentially expressed in TH cells. For this plot, up- and downregulated transcripts were analyzed separately, and transcripts differentially
expressed in opposing directions are therefore included in the counts. (B,C) Principal component analysis (PCA) of gene expression profiles of transcripts differentially
expressed in (B) TH1 and (C) TH17 cells. Diseased mice showed higher TH cell-specific expression levels (Supplementary Table 7). PC, principal component; y-axis
unit: standard deviations. (D,E) Examples of expression levels of the TH1 signature molecule (D) Tbx21 and the TH17 signature molecule (E) Il17f. Diseased mice
showed significantly higher expression levels of Tbx21, yet only OSE4 mice showed an increased expression of Il17f. Furthermore, the TH1 signature molecule Ifng
was expressed significantly higher only in OSE4; the TH17 signature molecules Rorc and Il17a were not differentially expressed in any contrast
(Supplementary Table 8). Significance levels: n.s.: p ≥ 0.05, * adjusted p < 0.05, *** adjusted p < 0.001.
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Gene Expression in OSE Overlaps With TH
Cell-Specific Transcripts
TH cell differentiation was identified as a key pathway in the
etiology of MS (13). We, therefore, analyzed whether gene
expression changes in EAE models were related to TH cell
differentiation. To this end, gene expression profiling of in vitro
polarized TH1 and TH17 cells was conducted, derived from OSE
mice. Compared to naïve TH0 cells, 8× more transcripts were
differentially expressed specifically in TH1 than in TH17 cells
(Figure 3A). None of the transcripts differentially expressed in
both TH1 and TH17 were regulated in opposite directions.
We examined via PCA whether the expression of TH1- and
TH17-specific, differentially expressed probes was higher in EAE
models than controls. The first component of TH1-and TH17-
specific gene expression explained 49.6 and 68.6% of the variance,
respectively. For both TH cell types, the first component of cell-
specific transcripts was significantly higher in all disease groups
than in controls, with the highest levels for OSE4 (Figures 3B,C,
Supplementary Table 7). Among signature molecules for TH1
cells, Tbx21 (T-bet) was significantly upregulated in all diseased
mice, Ifng only in OSE4 (Figure 3D, Supplementary Table 8). Of
the examined TH17markers, only Il17f was upregulated in OSE4,
neither Rorc nor Il17a were differentially expressed (Figure 3E,
Supplementary Table 8).
After correction for multiple testing, the CDT, OSE4sp, and
OSE1ex analysis sets were significantly enriched for TH1- and
TH17-specific transcripts (Table 2). In the case of MOG4sp
transcripts, the overlap was lower and only significant for TH1-
specific probes. These experiments indicate a stronger overlap of
knownMS-associated immune responses involving TH cells with
OSE than with MOG EAE.
Finally, we analyzed whether EAE-associated genes
differentially expressed in TH1 or TH17 cells were more
closely connected to human MS. To this end, we intersected
the lists of EAE-specific and TH-specific transcripts. Immune-
related biological processes were overrepresented for CDT,
OSE4sp, and OSE1ex genes intersected with TH1-specific genes.
(Supplementary Table 9, Supplementary Figure 6). No terms
were significantly overrepresented for any TH17-specific or
MOG4sp genes.
CDT and OSE1ex genes differentially expressed in TH1 cells
were significantly enriched for the IMSGC MS risk genes (p
< 7 × 10−4, Table 3). The enrichment for OSE4sp did not
withstand correction for multiple testing. Neither any of the
TH17-specific gene sets nor the genes from the MOG4sp group
were enriched for these risk genes. Thus, we conclude that OSE
entails gene expression changes involving human MS gene risk
genes, especially in TH1 cells, which were not observed to the
same degree for MOG EAE.
DISCUSSION
With the identification of over 230MS risk loci in recent GWAS,
we move closer to understanding the etiology of MS. Further
research relies on adequate animal models that have to be
reassessed in the context of GWAS data. Given the interplay
of genetics and environment in human MS, spontaneous EAE
models like OSE might be more apt for studying the genetic risk
component of MS than induced EAE models that require active
experimental manipulation. In the present study, we performed
spinal cord gene expression profiling to, first, characterize
differences between spontaneous OSE and MOG-induced EAE
and, second, to analyze the relationship of both models to human
MS risk genes and TH cell biology.
OSE May Reflect the Etiology of MS Better
Than MOG EAE Does
In comparison to MOG EAE, gene expression changes in OSE
were stronger and more closely linked to immune pathways.
This might reflect a more complex mode of disease induction
in OSE than is the case for MOG EAE. OSE features active
B and T cell cooperation, a mechanism highly relevant for
the pathophysiology of human MS, as demonstrated by the
effectivity of B cell-depleting treatments (10, 11). More than
MOG EAE, OSE-specific transcripts were enriched for both
humanMS risk genes and TH cell-specific transcripts and showed
TABLE 2 | Enrichment of TH-specific transcripts.
DE transcript group DE genes Cell type Overlapping genes p-value Adjusted p-value
CDT 2,014 TH1 150 <1 × 10
−5
<8 × 10−5
TH17 28 2.0 × 10
−2 4.0 × 10−2
OSE4sp 2,362 TH1 195 <1 × 10
−5
<8 × 10−5
TH17 36 2.0 × 10
−3 8.0 × 10−3
MOG4sp 469 TH1 35 1.1 × 10
−2 3.3 × 10−2
TH17 7 9.8 × 10
−2 9.8 × 10−2
OSE1ex 693 TH1 61 2.0 × 10
−5 1.2 × 10−4
TH17 16 1.0 × 10
−3 5.0 × 10−3
1,080 TH1- and 145 TH17-specific transcripts were examined. P-values were computed using 100,000 permutations. Enrichments significant after Holm-Bonferroni correction for
multiple testing (eight tests) are highlighted in bold font (adjusted p-value < 0.05). DE, differentially expressed; WT, wildtype; CDT, common disease transcripts (differentially expressed
for both contrasts OSE4-OSE0 and MOG4-CFA but not in the two control contrasts OSE0-WT or CFA-WT); OSE4sp, OSE4-specific transcripts (differentially expressed for the contrast
OSE4-OSE0 but not in MOG4-CFA, OSE0-WT, or CFA-WT); MOG4sp, MOG4-specific transcripts (differentially expressed for the contrast MOG4-CFA but not in OSE4-OSE0, OSE0-WT,
or CFA-WT); OSE1ex, OSE1-expressed transcripts (differentially expressed in OSE1-OSE0 but not in OSE0-WT or CFA-WT).
Frontiers in Immunology | www.frontiersin.org 8 September 2020 | Volume 11 | Article 2165
Faber et al. EAE and MS Risk Genes
TABLE 3 | Enrichment of MS susceptibility genes among TH-specific transcripts.
DE transcript group Cell type EAE TH cell list size Overlapping genes p-value Adjusted p-value
CDT TH1 150 10 6.5 × 10
−4 5.2 × 10−3
TH17 30 3 2.1 × 10
−2 1.1 × 10−1
OSE4sp TH1 215 10 9.7 × 10
−3 5.8 × 10−2
TH17 41 3 4.7 × 10
−2 1.6 × 10−1
MOG4sp TH1 37 1 5.1 × 10
−1 5.1 × 10−1
TH17 7 1 1.3 × 10
−1 2.6 × 10−1
OSE1ex TH1 60 6 1.1 × 10
−3 7.7 × 10−3
TH17 16 2 3.9 × 10
−2 1.6 × 10−1
The p-values were computed using 100,000 permutations. Enrichments significant after Holm-Bonferroni correction for multiple testing (eight tests) are highlighted in bold font (adjusted
p-value <0.05). DE, differentially expressed; WT, wildtype; CDT, common disease transcripts (differentially expressed for both contrasts OSE4-OSE0 and MOG4-CFA but not in the
two control contrasts OSE0-WT or CFA-WT); OSE4sp, OSE4-specific transcripts (differentially expressed for the contrast OSE4-OSE0 but not in MOG4-CFA, OSE0-WT, or CFA-WT);
MOG4sp, MOG4 -specific transcripts (differentially expressed for the contrast MOG4-CFA but not in OSE4-OSE0, OSE0-WT, or CFA-WT); OSE1ex, OSE1-specific transcripts (differentially
expressed in OSE1-OSE0 but not in OSE0-WT or CFA-WT).
an overrepresentation of immune-specific gene sets. We thus
hypothesize that OSE shows advantages over MOG EAE in
studying the functional role of human MS risk genes and their
associated immune pathways.
Nevertheless, many of the differentially expressed genes
indicate that both EAE models faithfully recapitulate
critical functional pathways of MS, especially regarding
the role of antigen presentation and CD4+ T cells in MS
immunopathogenesis (25, 26). Transcripts for the HLA genes
H2-Eb1 and H2-Ab1, homologous to HLA-DRB5 and HLA-
DQB1, were among the most differentially expressed probes. The
alleles HLA-DRB5∗01:01 and HLA-DQB1∗06:02 are part of the
DR15-DQ6 haplotype and are, most likely because of linkage
disequilibrium with HLA-DRB1∗15:01, strongly associated with
MS risk (27). In MS, memory B cells mediate autoproliferation
of brain-homing TH1 cells in a HLA-DRB1
∗15:01-dependent
manner (28). Interestingly, the antigen-presenting function of
MOG-specific B cells is, in cooperation with T cells, important
for the development of OSE (10). Among putative non-MHC
MS risk genes (1, 2), Cd86, Cd52, and Cd74 showed very robust
support for differential expression.
We could thus show that EAE, and in particular OSE,
constitutes a valuable model for studying the role of human MS
risk genes. Several previous studies support this finding: First,
humanized EAE models successfully replicated HLA-related
risk variants, including HLA-DRB∗15:01 (29). Second, knockout
mice lacking the MS-associated Il7r are resistant to EAE (30).
Third, shared human and EAE risk loci exist that are linked to
TH cell differentiation (31). Fourth, an overlap of upregulated
genes between myelin-reactive T cells from MS patients and
encephalitogenic CD4+ T cells isolated from EAE was described
(32). Fifth, in a passive-transfer EAE study, several MS risk genes
were suggested to be implicated in the transition from in vitro-
generated MOG-specific TH17 cells to encephalitogenic CD4
+ T
cells (33).
Functional pathways involving MS risk genes interact with
environmental factors to trigger an autoimmune response, as
demonstrated by the role of epigenetic factors for MS risk (1, 34).
Spontaneous EAE models might resemble gene-environment
interactions more faithfully than MOG EAE does. For instance,
in a spontaneous EAEmodel, disease onset could be prevented in
mice kept under germ-free conditions (7). In this model, a higher
incidence of EAE was observed following the transfer of the
human gut microbiome fromMS patients than when transferring
the microbiome from the patient’s healthy twin (8).
TH1-Specific Transcripts Are Enriched for
MS Risk Genes
Our gene set analyses point at a central role of lymphocyte
activation in EAE induction and shed light on the ongoing
controversy regarding the relative importance of TH1 and TH17
cells in mediating CNS autoimmunity (35). In accordance with
previous studies (9), we observed a higher differential expression
of selected TH1- than of TH17-specific transcripts in diseased
mice. Interestingly, a high TH1/TH17 ratio is indicative of a
lesion distribution pattern characterized by prominent spinal
cord involvement, as is the case for both EAEmodels investigated
in our study (12, 15, 36).
CDT and OSE1ex transcripts differentially expressed in TH1
cells were significantly enriched for MS risk genes (Table 3). We
did not observe such an enrichment for transcripts differentially
expressed in TH17 cells. Albeit also OSE4sp genes were only
enriched for risk genes in TH1 cells at nominal significance
(unadjusted p = 0.0097), TH1-expressed MOG4sp transcripts
showed no trend for the enrichment of MS risk genes at
all (unadjusted p = 0.51). In GO overrepresentation analyses,
immune-related biological processes like positive regulation of T
cell proliferation were significant for OSE4sp-genes differentially
expressed in TH1 cells, but no GO gene sets at all were
overrepresented in TH1-specific MOG4sp genes. In the context
of TH1-driven immune responses, the OSE model might thus be
linked more closely to human MS risk genes than MOG35−55
EAE is. However, TH17 cells can shift toward a TH1 phenotype
in EAE (37, 38). The TH1 markers analyzed in the EAE models
may, accordingly, reflect expression in a significant proportion of
former TH17 cells. Therefore, our findings do not argue against a
relevant impact of TH17 cells in either EAE model.
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Expression Patterns Across Different
Disease Stages Can Be Studied Using OSE
Most genes differentially expressed in OSE1 mice were also
recapitulated in severely affected OSE4 mice and showed the
same direction of regulation in both disease stages. Many factors
active in severe EAE thus also influence EAE during a mild
or, potentially, early disease course. Effective immunotherapy is
facilitated if the same biological pathways are continuously active
throughout the entire disease. For example, the gene set response
to interferon-beta was highly overrepresented in both OSE1ex
and CDT and Cd52 was differentially expressed in all diseased
mice. Studying mild OSE cases might, therefore, constitute an
interesting model for defining the initial triggers of MS and the
identification of novel therapeutic options.
LIMITATIONS
Our gene expression analysis of two EAE models had several
limitations: First, the microarrays used covered only part of the
murine transcriptome and thus, some MS risk genes could not
be analyzed. Second, the statistical power of our analyses was
restricted by the sample size. Third, the initial phases of EAE are
hard to define since the disease develops over a short period. We
thus analyzed mild OSE cases as a proxy for early disease. It is,
however, unknown whether these animals would have developed
more severe EAE later.
CONCLUSIONS
Although hundreds of genetic MS risk loci have been identified,
their functional role in the etiology of the disease still has
to be resolved. Ideally, suitable animal models recapitulate
molecular and functional pathways involving these genes.
They may thus move research closer to the primary cause
and etiology of MS, thereby supporting the identification of
effective immunotherapies. No animal model fully reflects a
heterogeneous human disease like MS and each EAE model
available today only replicates a part of the human disease.
Researchers will thus continue to study different aspects of
MS using a variety of EAE models. Our results indicate that
OSE, with its closer link to MS risk genes and TH cell
biology, may be better suited for studying the etiology of
MS and for defining specific therapeutic targets than MOG-
induced EAE is. Future studies will show whether OSE can
fulfill this promise to model the human MS genetic risk
landscape faithfully.
DATA AVAILABILITY STATEMENT
The datasets presented in this study can be found in online
repositories. The names of the repository and accession




The animal study was reviewed and approved by
Tierschutzkommission der Regierung von Oberbayern,
Munich, Germany.
AUTHOR CONTRIBUTIONS
HF, GK, PW, and FW contributed to the original conception and
design of the study. HF, GK, and PW conducted experiments.
DK and TA devised the statistical analyses. DK, BP, and
TA conducted statistical analyses. BM-M and FW supervised
the study. HF and TA drafted the manuscript. All authors
contributed to manuscript revision, read, and approved the
submitted version.
FUNDING
TA was supported by the German Federal Ministry of
Education and Research (BMBF) through the DIFUTURE
consortium of the Medical Informatics Initiative Germany
(grant 01ZZ1804A) and by the European Union’s Horizon
2020 Research and Innovation Programme (grant MultipleMS,
EU RIA 733161). TA and BM-M were supported by the
BMBF through the Integrated Network IntegraMent,
under the auspices of the e:Med Programme (grant
01ZX1614J). GK was supported by the European Research
Council starting grant (GAMES; 635617), German research
foundation (DFG) SFB TR-128 (Project A1), and by the Max
Planck Society.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fimmu.
2020.02165/full#supplementary-material
Supplementary Figure 1 | Disease course of MOG EAE in C57BL/6 mice. MOG
EAE was induced in C57BL/6 mice as described in the Methods. The plot shows
mean clinical scores (n = 4) and the standard error of the mean. The disease
score of MOG EAE mice began to increase on day ten. The mice were sacrificed
when they reached a score of 4. Control mice (CFA) consistently remained at a
disease score of 0.
Supplementary Figure 2 | Efficiency of TH1 and TH17 differentiation. (A) T cells
from OSE mice were activated under TH1- and TH17-polarizing conditions and
analyzed for intracellular IL-17 and IFN-γ cytokine expression by flow cytometry.
The data represent the percentage of cytokine-producing cells in the gated CD4+
populations of naïve (TH0), TH1, and TH17 cells. (B) Quantification of IL-17 and
IFN-γ in the culture supernatants of TH1 and TH17 cells by ELISA. The plots show
the mean and the standard error of the mean (SEM). (C) IL-17 and IFN-γ mRNA
expression of naïve (TH0), TH1-, and TH17-polarized cells quantified by real-time
PCR. The data are representative of three independent experiments. The plots
show the mean and SEM.
Supplementary Figure 3 | Overrepresented immune system pathways in OSE
and MOG EAE contrasts. The plots show overrepresented GO terms that are
descendants of the term Immune System Process (Supplementary Table 4) for
the contrasts (A) OSE1-OSE0, (B) OSE4-OSE0, (C) MOG4-CFA, and (D)
MOG4-OSE4. The -log10(FDR) from hypergeometric tests is shown on the x-axis
and used for coloring the plots (darker colors represent lower FDRs).
Supplementary Figure 4 | The top 40 overrepresented immune system
pathways in the differentially expressed transcripts groups. The plots show the top
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40 overrepresented GO terms that are descendants of the term Immune System
Process (Supplementary Table 4) for the transcript groups (A) CDT, common
disease transcripts (differentially expressed for both contrasts OSE4-OSE0 and
MOG4-CFA but not in the two control contrasts OSE0-WT or CFA-WT), (B)
OSE4sp, OSE4-specific transcripts (differentially expressed for the contrast
OSE4-OSE0 but not in MOG4-CFA, OSE0-WT, or CFA-WT), (C) OSE1ex,
OSE1-expressed transcripts (differentially expressed in OSE1-OSE0 but not in
OSE0-WT or CFA-WT). Note that no GO terms that are descendants of the term
Immune System Process were significantly overrepresented for the group
MOG4sp, MOG4-specific transcripts (differentially expressed for the contrast
MOG4-CFA but not in OSE4-OSE0, OSE0-WT, or CFA-WT). The -log10(FDR) from
hypergeometric tests is shown on the x-axis and used for coloring the plots
(darker colors represent lower FDRs).
Supplementary Figure 5 | Expression levels of Cd74 and Icam1. Diseased mice
showed an increased expression of (A) Cd74 and (B) Icam1
(Supplementary Table 2). Significance levels: ∗ adjusted p < 0.05, ∗∗ adjusted p
< 0.01, ∗∗∗ adjusted p < 0.001.
Supplementary Figure 6 | The top 40 overrepresented immune system
pathways in the differentially expressed transcripts groups intersected with
TH1-specific genes. The plots show the top 40 overrepresented GO terms that are
descendants of the term Immune System Process (Supplementary Table 9) for
the transcript groups (A) CDT (common disease transcripts) intersected with
TH1-specific genes, (B) OSE4sp (OSE4-specific transcripts) intersected with
TH1-specific genes, (C) OSE1ex (OSE1-expressed transcripts) intersected with
TH1-specific genes. Note that no GO terms were significantly overrepresented for
any TH17-specific or MOG4sp genes. The -log10(FDR) from hypergeometric tests
is shown on the x-axis and used for coloring the plots (darker colors represent
lower FDRs).
Supplementary Table 1 | Results from k-means clustering (Figure 1A).
Supplementary Table 2 | Differential expression results for all analyzed contrasts.
FC, fold change; CI, 95% confidence interval.
Supplementary Table 3 | Comparison of fold changes in expression levels
between contrasts (Figures 1C,D). CI, 95% confidence interval.
Supplementary Table 4 | Results from WebGestalt gene ontology (GO)
over-representation analyses (ORA) for the analysis groups CDT, OSE4sp,
MOG4sp, and OSE1ex (see the legend of Table 1 and Supplementary Figure 5)
as well as the contrasts OSE1-OSE0, OSE4-OSE0, MOG4-CFA, and MOG4-OSE4
(Supplementary Figure 4). FDR, 5% false discovery rate. Gene sets that are
labeled in bold if they are descendants of the GO term “Immune System Process”.
Supplementary Table 5 | Differential expression results for the analysis groups
(see the legend of Table 1) CDT, CDT, OSE4sp, MOG4sp, OSE1ex, and OSE1sp.
OSE1sp transcripts were differentially expressed in OSE1-OSE0 but not in any
other contrast. FC, fold change, CI, 95% confidence interval. For CDT transcripts,
separate coefficients are provided for the two contrasts MOG4-CFA and
OSE4-OSE0.
Supplementary Table 6 | Results from the principal component analysis (PCA) of
gene expression profiles of putative MS risk genes (Figure 2A). FC, fold change,
CI, 95% confidence interval. P-values were adjusted for multiple testing using
Holm-Bonferroni correction.
Supplementary Table 7 | Results from the principal component analysis (PCA) of
gene expression profiles of TH cell-specific transcripts (Figures 3B,C). FC, fold
change; CI, 95% confidence interval. P-values were adjusted for multiple testing
using Holm-Bonferroni correction.
Supplementary Table 8 | Differential expression results for selected TH1 and
TH17 signature molecules (Figures 3D,E). DE, differentially expressed.
Supplementary Table 9 | Results from Webgestalt gene ontology (GO)
over-representation analyses (ORA) for the analysis groups CDT, OSE4sp, and
OSE1ex (see the legend of Table 1) among TH1-specific transcripts
(Supplementary Figure 6). For MOG4sp or TH17-specific transcripts, no
significant gene sets were found. FDR, 5% false discovery rate. Gene sets that are
labeled in bold if they are descendants of the GO term “Immune System Process”.
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